Orion Portfolio Solutions LLC Grows Stock Position in Cencora, Inc. (NYSE:COR)

Orion Portfolio Solutions LLC grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 367.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 58,412 shares of the company’s stock after purchasing an additional 45,921 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Cencora were worth $13,124,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Whittier Trust Co. grew its position in Cencora by 0.6% in the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock worth $1,765,000 after acquiring an additional 44 shares during the period. Shepherd Financial Partners LLC boosted its holdings in Cencora by 0.9% in the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company’s stock valued at $1,223,000 after purchasing an additional 46 shares during the period. WASHINGTON TRUST Co grew its position in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after buying an additional 46 shares in the last quarter. JFS Wealth Advisors LLC grew its holdings in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after acquiring an additional 46 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its stake in Cencora by 1.1% in the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company’s stock valued at $1,003,000 after buying an additional 47 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. This represents a 21.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the transaction, the chairman now owns 317,913 shares of the company’s stock, valued at $85,680,732.63. This represents a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock valued at $8,034,778 in the last 90 days. 10.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on COR shares. Wells Fargo & Company boosted their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Mizuho assumed coverage on Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average price target of $280.20.

Cencora Stock Performance

NYSE:COR opened at $275.16 on Friday. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $275.57. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market cap of $53.36 billion, a PE ratio of 39.14, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The firm’s fifty day simple moving average is $253.81 and its 200-day simple moving average is $241.18.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio is currently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.